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The path for metal complexes to a DNA target
Alexis C. Komor and Jacqueline K. Barton*
The discovery of cisplatin as a therapeutic agent stimulated a new era in the application of transition
metal complexes for therapeutic design. Here we describe recent results on a variety of transition metal
complexes targeted to DNA to illustrate many of the issues involved in new therapeutic design. We
describe first structural studies of complexes bound covalently and non-covalently to DNA to identify
potential lesions within the cell. We then review the biological fates of these complexes, illustrating the
key elements in obtaining potent activity, the importance of uptake and subcellular localization of the
complexes, as well as the techniques used to delineate these characteristics. Genomic DNA provides a
challenging but valuable target for new transition metal-based therapeutics.
Introduction
Since the successful application of cisplatin as an anticancer
drug, the field of inorganic medicinal chemistry has undergone
a revolution.1 Several additional platinum complexes have
achieved FDA approval for cancer treatment.2 Two ruthenium
complexes are currently in clinical trials,3,4 and studies on the
biological eﬀects of potential metal-based therapeutics are
being published at an increasing rate. Anticancer compounds
have a myriad of targets (DNA, proteins, membranes, etc.), and
in fact the true lesion responsible for the biological activity of a
compound is diﬃcult to determine.5 Nevertheless, this article
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focuses on compounds that are not unlike cisplatin, in that the
complexes are thought to have DNA as their main target in cellulo.
Here we discuss studies of several metal complexes to
explore their diﬀerences in structural interactions with DNA,
their biological fates inside the cell, and the tools and techni-
ques being used to probe the path taken by the small molecule
in reaching its DNA target. Establishing cellular uptake and
even the subcellular distributions of the metal complexes are
critically important in understanding and optimizing their
activity. While the subtle hydrolysis reactions associated with
cisplatin uptake probably could not have been strategically
designed, they are key to its mode of action. This review is
illustrative rather than comprehensive in its approach, yet
hopefully these illustrations provide a foundation for consider-
ing strategies for new design and for elucidating mechanisms
of action.
DNA as a target
DNA represents a fruitful target for metal complexes. DNA can
function as a ligand either through interactions with the sugar
phosphate backbone or coordination to the bases. Moreover,
non-covalent interactions with DNA lead to additional targets,
and greater specificity, through an ensemble of interactions in
the DNA grooves and base stack.
Covalent interactions
It has been widely accepted since the 1970’s that DNA is the
biological target of cisplatin in vivo.6,7 However, the nature of
the adduct formed between cisplatin and DNA was not deter-
mined until the 1980’s. This interaction was proposed to be
an intrastrand cross-link between the N7 atoms of adjacent
guanines and cisplatin based on the results of numerous
biochemical studies.8,9 This adduct was further characterized
by gel electrophoresis and it was found that the DNA duplex
was bent by B401.10 However, this adduct was not fully
structurally characterized by X-ray crystallography until 1995,
when the Lippard group published the 2.6 Å resolution
crystal structure of cisplatin bound to a double-stranded DNA
dodecamer (Fig. 1).11
In this structure, the duplex is bent considerably toward the
major groove but without disruption of the Watson–Crick
hydrogen bonding. In fact, the duplex is distorted to such a
degree that the duplex changes conformation from B-DNA to
A-DNA throughout most of the duplex. Such a significant
distortion of the DNA is likely readily recognized by a host of
cellular proteins. How eﬃciently such lesions are recognized
and repaired rather than initiating a protein response and
signaling cascade, is a question we still need to understand
and which may make the diﬀerence between biological eﬃcacy
and little reaction.12
Intercalation
Metallointercalation is a DNA binding mode that has been
extensively studied. The term was coined by Lippard and
coworkers in studies of square planar Pt complexes with
DNA.13 As with organic intercalators, these planar complexes
containing aromatic heterocyclic ligands could stack among
the DNA base pairs. However, the lack of site-specificity
inherent in intercalation by a planar complex made detailed
structural characterization diﬃcult. The first structural char-
acterization of metallointercalation was the 1.1 Å resolution
crystal structure of the platinum complex [Pt(SEtOH)(terpy)]+
intercalated into the dinucleotide dimer deoxy CpG.14 Although
not able to establish long range structural perturbations to DNA
associated with intercalation, this structure did reveal that
associated with intercalation, the DNA unwinds to accommo-
date the metal complex between bases and the pucker of the
sugar rings changes geometry. This alternate sugar puckering
was suggested as the basis for the ‘‘neighbor exclusion
principle’’ associated with DNA intercalation, where at most
intercalators bind in every other interbase-pair site.
In succeeding years, our laboratory focused on intercalation
by octahedral complexes containing at least one aromatic
heterocyclic ligand for stacking, or partial intercalation, in
between base pairs. The symmetry and functionality associated
with the non-intercalated ligands could then provide the basis
for highly specific interactions with several bases along the
groove of DNA, once oriented by stacking in the helix of the
intercalated ligand. In particular, we found the enantioselective
intercalative binding of right-handed D-complexes into right-
handed B-DNA.15 One of the first structural characterizations of
metallointercalation into a long DNA duplex was thus provided
from the 1.2 Å resolution crystal structure of the sequence-
specific rhodium intercalator, D-a-[Rh[(R,R)-Me2trien]phi]
3+,
Fig. 1 Crystal structure at 2.6 Å resolution of the intrastrand crosslink between
cisplatin and the N7 atoms of adjacent guanines.11 The platinum center is shown
as a light grey sphere, and its four nitrogen-based ligands are shown in blue. DNA
is shown in grey. The dodecamer duplex is bent considerably towards the major
groove, and the structure is no longer B-form DNA, but mostly A-form through-
out the duplex.
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bound to a duplex octamer (Fig. 2).16 The complex was
designed to target the sequence 50-TGCA-30 through a mix of
hydrogen bonding and methyl–methyl interactions in the DNA
major groove. The complex was also shown as a result of its
sequence-specificity to inhibit the binding of sequence-specific
DNA-binding proteins, a first step in specifically inhibiting
gene expression.17
Critically, the structure obtained provided detailed informa-
tion on how metallointercalation in general modifies the con-
formation of DNA. In this structure, intercalation occurs from
the major groove, with the aromatic intercalating phi ligand
p-stacking with the p-orbitals of the flanking base pairs, similar
to the stacking of consecutive base pairs in duplex DNA. This
structure also confirmed the conformational changes revealed
by shorter intercalated oligonucleotides such as doubling of the
rise, buckling of the base pairs flanking the intercalation site,
and a slight unwinding of the DNA localized at the site of
intercalation. Interestingly, there were no long range eﬀects on
the DNA structure, no bending or kinking of the helix. Indeed,
even the alternating sugar-pucker was not evident. The metal-
lointercalator was simply like another base pair in the helical
stack.
Structural characterization of intercalation from the minor
groove was recently obtained from two independent crystal
structures of dppz complexes of Ru(II) intercalated into duplex
DNA. The first is the 0.92 Å resolution structure of two
D-[Ru(bpy)2(dppz)]
2+ complexes intercalated from the minor
groove into a duplex 12-mer containing two mismatched
sites.18 There are also two ruthenium complexes bound to the
mismatched sites via insertion (vide infra), and the extruded
adenosines p-stack with the bpy ligands of the intercalated
complexes, serving to stabilize the intercalated complex in the
minor groove (Fig. 3). Intercalation of this complex from the
minor groove was in contrast to NMR19,20 and competitive
fluorescence studies,21 both of which suggested that inter-
calation of the ruthenium complex occurred from the major
groove. Crystal packing forces may play a role here in directing
intercalation from the minor groove side; in any case it is clear
that the energetic diﬀerences between intercalation from the
major groove versus minor groove must be small. Furthermore,
this structure showed the doubling of the rise of the DNA at
each intercalation site, and an unwinding of the base pairs to
accommodate the complexes. Interestingly, while the rise is
doubled at each intercalation site, the rise between the base
pairs with no metal complex bound is reduced from the 3.3 Å
that is expected, consistent with p-stacking interactions
between the extruded mismatches and the ancillary bpy ligands
being the dominating interaction that may be directing inter-
calation from the minor groove.
The second set of structures show the binding of
L-[Ru(phen)2(dppz)]
2+ to two diﬀerent duplex 10-mers.22 These
structures reveal three diﬀerent conformations of intercalation
for the same complex. Namely, when intercalated at the TA/TA
Fig. 2 The 1.2 Å resolution crystal structure of the sequence-specific rhodium
intercalator, D-a-[Rh[(R,R)-Me2trien]phi]
3+, bound to a duplex octamer.16 The
complex binds specifically to 50-TGCA-3 0 . There are two Van der Waals Me–Me
interactions between the metal complex ligand and T (T shown in blue,
interaction shown with the black dotted line), and a hydrogen bond between
the NH group on the metal complex ligand and the O6 of G (G shown in green,
interaction shown with the black dotted line). This structure displays the doubling
of the rise of the DNA, buckling of the adjacent base pairs, and a slight
unwinding of the DNA upon intercalation.
Fig. 3 The 0.92 Å resolution structure of two D-[Ru(bpy)2(dppz)]
2+ complexes
intercalated from the minor groove into a duplex 12-mer containing two AA
mismatched sites.18 The mismatches are extruded from the base stack by two
other D-[Ru(bpy)2(dppz)]
2+ complexes that are metalloinserted at these sites. The
extruded bases (shown in blue) p-stack with the bpy rings of the intercalated
metal complexes (interactions shown in black, metal complexes shown in red).
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central step of the oligonucleotide d(CCGGTACCGG)2, the
complex is intercalated deeply, perpendicularly, and symme-
trically into the base stack from the minor groove. However,
when the complex intercalates at the terminal GG/CC step, the
intercalation geometry is shallower and angled. Finally, this
angled intercalation allows for the phenanthroline ligands
to semi-intercalate into the neighboring duplex. This ‘‘semi-
intercalation’’ was also seen in a structure of L-[Ru(TAP)2(dppz)]
2+
bound to a duplex 10-mer.23
These various structural characterizations of metallointerca-
lation highlight the versatility of this binding mode, and likely
also the shallow energy profile among diﬀerent intercalative
binding modes. Likely the structural diversity reflects the
sequence selectivity associated with the diﬀerent complexes,
where the non-intercalating interactions in the DNA groove
lead to some structural variations. But none of these conforma-
tional changes yield dramatic changes in DNA structure, like
the bend in DNA generated by a Pt crosslink. In the context of
therapeutic design, the fact that metallointercalators cause no
major structural distortions in DNA needs to be considered.
Intercalators generally, especially those that have no sequence-
specificity, have little therapeutic applicability. Perhaps it is
the fact that a strongly defined DNA lesion is not produced
with intercalation that limits the biological consequences for
metallointercalators.
Insertion
Rhodium metalloinsertors, as described in our laboratory, bind
to mismatches in DNA with high aﬃnity and specificity.24,25
While it was known that these compounds could preferentially
target thermodynamically destabilized mismatches in DNA
over matched base pairs by a factor of over 1000,26 for ten
years there was no structural information on the interaction
between these metal complexes and mismatched DNA. The
1.1 Å resolution crystal structure of [Rh(bpy)2(chrysi)]
3+ bound
to an AC mismatch revealed the binding mode to be metallo-
insertion, where the chrysi ligand inserts into the base stack via
the minor groove and ejects both mismatches bases (Fig. 4).27
Metalloinsertion of this complex results in only small con-
formational changes in the duplex near the binding site but a
large perturbation is associated with the ejection of the mis-
matched bases into the DNA groove. The structure also explains
the enantiospecificity of binding of [Rh(bpy)2(chrysi)]
3+; the
deep insertion of the complex within the minor groove with
no increase in base pair rise results in a steric clash between the
ancillary ligands and the sugar phosphate backbone if the left-
handed isomer were to be bound. For intercalation, in contrast,
where there is an increase in rise at the binding site, enantio-
selective intercalation requires a much bulkier ancillary ligand
than bpy.28 As with the case of cisplatin, this structure may also
suggest the basis for the biological activity of these complexes.
Ejection of the mismatched bases results in a large lesion that
could be easily recognized in vivo. This lesion likely is respon-
sible for the selective cell death of MMR-deficient cells over
MMR-proficient cells following rhodium treatment, as there are
1000 times as many mismatches in the MMR-deficient cells.
This binding conformation has been corroborated by
additional crystal structures of this same compound bound to
diﬀerent mismatches.29 Furthermore, the generality of metallo-
insertion as a binding mode for diﬀerent bulky metal complexes
has been established by the crystal structure mentioned earlier,
that of D-[Ru(bpy)2(dppz)]
2+ bound by insertion at two mis-
matched sites.18 Again, the information garnered from these
structures is instrumental in unraveling the mechanism of
action of these therapeutic agents, and thus in the development
of future agents with improved biological activity.
Biological activities of metal complexes
Undeniably, optimizing a compound as a therapeutic requires
the complete assessment of its biological activity in vitro. Here
we focus on the biological activity in cellulo of several classes of
transition metal complexes that are thought to target DNA. As
the activities of cisplatin and other platinum compounds have
been extensively discussed elsewhere,12,30,31 we describe here
the characterization of non-platinum-based therapeutics.
Polypyridyl complexes
The biological activities of countless ruthenium polypyridyl
complexes have been reported in the literature and have been
the subject of many reviews.32 Indeed, the exploration of
biological activities of polypyridyl complexes began more than
fifty years ago in classic studies by Dwyer and coworkers.33 At
that stage, no biological target was identified, but the more
recent studies on coordinatively saturated metal complexes
suggest that DNA was likely the target for the full family of
complexes examined earlier.
Many more studies have been conducted on ruthenium
complexes that bind DNA covalently, by analogy to cisplatin,
Fig. 4 The 1.1 Å resolution structure of D-[Rh(bpy)2(chrysi)]
3+ bound to an AC
mismatch.27 The rhodium complex, shown in red, inserts into the DNA from the
minor groove and completely ejects the mismatches bases, shown in blue.
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than those which are coordinatively saturated and inert to
substitution, binding non-covalently. In one of the earliest
studies, Novakova and coworkers studied four chloropolypyr-
idyl ruthenium complexes (Fig. 5) in murine and human tumor
cell lines. Interestingly, only the complex with three leaving
chloride ligands, mer-[Ru(terpy)Cl3], displayed significant cyto-
toxicity. While the binding aﬃnities of the diﬀerent complexes
could not explain this discrepancy, it was discovered that only
the mer-[Ru(terpy)Cl3] complex had the ability to form inter-
strand crosslinks in the DNA, thus harkening on the importance
of specific lesions and structural distortion in determining
biological activities, not simply avidity for binding DNA.34
In a more recent study conducted by Tan and coworkers,
several inert ruthenium polypyridyl complexes were studied,
three ruthenium complexes containing a b-carboline ligand,
along with the control compound [Ru(phen)2(dppz)]
2+ (Fig. 6).
They observed that upon substitution of the dppz ligand for the
b-carboline ligand, the complex now accumulates in the
nucleus as well as the cytoplasm. Furthermore, the complexes
with b-carboline ligands are significantly more cytotoxic
towards HeLa cells, inducing apoptosis and autophagy, while
[Ru(phen)2(dppz)]
2+ does not. Since the cytotoxicities of the
b-carboline complexes correlated well with their DNA binding
aﬃnities, they concluded that genomic DNA may be their
primary target in cellulo.35 The comparative results with these
complexes, however, also suggest that the diﬀerential activities
of the complexes may depend on more than just aﬃnities. Both
cellular uptake and localization may be issues. Moreover the
bulkiness and geometry of the coordinated carboline ligand
may indicate that metalloinsertion plays some role in the
binding interaction.
The Sheldrick laboratory has focused on studies of a variety
of rhodium polypyridyl complexes that can bind both covalently
and non-covalently with DNA.36,37 A series of polypyridyl
rhodium complexes containing a facial tripodal (tpm), Cp*, or
thioether ([9]aneS3) ligand (Fig. 7) were synthesized and their
cytotoxicities towards the MCF-7 and HT-29 cell lines exam-
ined. They observed, in general, while keeping the facial ligand
constant, an increase in potency with increasing surface area
and hydrophobicity of the polypyridyl ligand. Furthermore, it
was found that for the polypyridyl ligands phen, dpq, and dppz,
the facial ligands had the eﬀect of increasing the cytotoxicity in
the order [Cp*]o [9]aneS3o tpm. This trend was found to be
consistent not with binding aﬃnity, but with the magnitude of
rhodium uptake into the cells.38–40 Some of these complexes
Fig. 5 Chemical structures of four ruthenium polypyridyl complexes studied by
Novakova and coworkers.34 Out of all four complexes, only themer-[Ru(terpy)Cl3]
complex displays significant cytotoxicity in human and murine tumor cell lines. Fig. 6 Four Ru(II) polypyridyl complexes studied by Tan and coworkers.35 All
three complexes with b-carboline as a ligand were cytotoxic towards HeLa cells,
whereas the control [Ru(phen)2(dppz)]
2+ complex was not.
Fig. 7 Chemical structures of the compounds studied by the Sheldrick
laboratory.38–41 An extensive structure-activity study was undertaken on all
complexes in the MCF-7 and HT-29 cell lines. Upon increasing the surface area
of the ‘‘L’’ ligand, the cellular uptake of the drug increased, resulting in an
increased potency of the drug.
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were furthermore found to selectively target lymphoma (BJAB)
cells over healthy leukocytes.41
Ruthenium arene complexes
There have been many studies exploring the cytotoxicities of
‘‘piano stool’’ complexes.42 Compounds of the type [(Z6-arene)-
Ru(L)(X)]+ (where L is a bidentate ligand and X is a halide,
Fig. 8) have been shown to exhibit anticancer activity,43 while
their analogs with three monodentate ligands are completely
inactive towards A2780 human ovarian cancer cells.44 In parti-
cular, the results from a few studies by the Sadler laboratory
revealed that while the identity of the halide and chelating
ligand had minor eﬀects on the biological activities of these
complexes towards A2780 cells, the size of the arene ligand had
a major eﬀect. The potency of the drug followed the trend
benzene o p-cymene o biphenyl o dihydroanthracene o
tetrahydroanthracene, which suggests increased cellular accu-
mulation enhances their activity.44,45 It was also noted that the
arene complexes of the form type [(Z6-arene)Ru(en)(Cl)]+ (en =
ethylenediamine) did not display cross-resistance with cisplatin,
suggesting an entirely diﬀerent mechanism of action of these
types of compounds.
Further studies confirmed that these complexes bind to
DNA and induce structural distortions to the DNA that are
distinct from those induced by cisplatin.46 Specifically, they
have been found to bind selectively to G bases in DNA oligo-
nucleotides, regardless of the presence of other biologically
relevant binding sites,47 along with partial intercalation of the
arene ligand into the base stack.48
Rhodium metalloinsertors
The biological activities of rhodium metalloinsertors, showing
a preferential activity in mismatch repair (MMR)-deficient cells,
reflect well on the initial strategy used for their design, namely
targeting DNA mismatches and therefore cells that have a
higher frequency of DNA mismatches, the MMR-deficient cells.
First studies were designed and carried out to establish in vitro
that the complexes bind to DNA mismatches with high aﬃnity
and specificity.24,25 Several years later, their unique biological
activity was characterized. Two metalloinsertors were found
to preferentially inhibit growth in MMR-deficient cells over
MMR-proficient cells (Fig. 9).49 Furthermore, while only the
D-[Rh(bpy)2(chrysi)]
3+ enantiomer binds to mismatches in vitro,
likewise only this enantiomer was found to possess this bio-
logical activity, implying that the biological activity of these
complexes originates from binding to mismatches in cellulo.
Further evidence to support this notion was achieved in a
succeeding study in which the ability of several diﬀerent
metalloinsertors with varying ancillary ligands to target
MMR-deficient cells preferentially was directly correlated with
their mismatch binding aﬃnities.50 A subsequent study on the
mechanism of activity of these metalloinsertors revealed that
not only do they selectively inhibit growth of MMR-deficient
cells, but after longer incubation times, they are also selectively
cytotoxic, inducing necrosis in the MMR-deficient cells.51 The
ability of these complexes to target MMR-deficient cells
over MMR-proficient cells with this selectivity is distinctive.
Commonly used chemotherapeutics, alkylators, DNA damaging
agents as well as cisplatin, all suﬀer from a selective toxicity
instead with MMR-proficient cells, leading to a build-up in
resistance to MMR-deficient cancers (Fig. 9).52 Moreover it
appears that the selective activity of metalloinsertors in
MMR-deficient cells is not only unique but also general to the
full family of metalloinsertors. The further development of this
class of compounds, then, might help overcome one of the
largest issues we have with current platinum-based therapeutics:
acquired or inherent resistance.
Cellular uptake of metal complexes
Establishing biological activity of small molecules and com-
plexes in the cellular milieu is clearly more complicated than
establishing chemical targets and structures in a test tube.
Fig. 8 Compounds studied by the Sadler laboratory.44–48 It was discovered that
as the lipophilicity of the arene ligand increased, the potency of the drug towards
A2780 cells increased. It was also found that complexes with L = en have a
mechanism of action distinct from cisplatin.
Fig. 9 Chemical structures (top) and biological activities (bottom) of the
rhodium metalloinsertor [Rh(bpy)2(chrysi)]
3+ (left), and the DNA alkylating agent
MNNG (right) studied in our laboratory.49 MMR-proficient (green) and MMR-
deficient (red) cells were treated with varying concentrations of each compound
and the proliferation of growth was quantified via a BrdU incorporation assay.
With the rhodium metalloinsertor, the MMR-deficient cells are preferentially
targeted over MMR-proficient cells, whereas the DNA alkylating agent targets
the MMR-proficient cells, a trend seen with many commonly used DNA-targeted
therapeutics.
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A key element underlying this complexity is whether and how
the complex enters the cell. Does it ever make it to its test tube
target?
Methods to monitor cellular uptake
Because transition metals like Rh, Ru, and Pt are not inherently
found in the cell, techniques that focus on detecting metals,
such atomic absorption spectroscopy (AAS) or inductively
coupled plasma mass spectrometry (ICP-MS) are invaluable to
monitor cellular uptake. The foundation of AAS is the aspect
that metal ions absorb strongly at discrete, characteristic
wavelengths. In this technique, the sample is suctioned into
an atomizer, which reduces everything in the sample to its
atomic states. The atoms are then irradiated, during which
time they will absorb light of a certain energy which equals a
specific electronic transition of a particular element. The
remaining radiation then passes through a monochromator
which picks out the wavelength of light specific to the metal of
interest, and sends it to the detector. Quantitative information
is obtained by taking the ratio of the flux without a sample to
the flux with the sample and converting to concentration using
the Beer–Lambert law.53,54
ICP-MS is highly sensitive and is applicable to a wide range
of metals. Furthermore, it is compatible with a wide range of
sample matrices, including many biologically relevant ones.
The sample is introduced into a spray chamber, where it is
nebulized into an aerosol. These small droplets are then
transferred to the inductively coupled plasma. The sample
droplets are atomized and ionized by the plasma, leading to
atomic, singly charged ions which are subsequently transferred
to the mass spectrometer, which is used to determine the
concentration of the metals of interest.55
Confocal fluorescence microscopy allows for the acquiring
of high-resolution 3-D images with low background interfer-
ence, and can be used to observe intracellular fluorescent
compounds.56 As such, confocal fluorescence microscopy has
been utilized in countless studies to probe the cellular uptake
of metal complexes, but only those that are luminescent.57
However, due to diﬀerences in the quantum yields among
diﬀerent luminescent compounds, this technique cannot be
utilized to quantify the amount of drug localized inside the cell.
Another technique that can be used to monitor uptake of
luminescent molecules is flow cytometry. In this technique,
cells are individually counted based on the amount of lumines-
cence inside of them. A stream of cells is passed through a laser
beam, and the instrument records their light scatter and
luminescence. The readout is a histogram showing the number
of cells versus luminescence intensity. Importantly, combining
either of these techniques with ICP-MS or AAS can give much
more information than either technique alone.
Relationships between drug uptake and activity
One major disadvantage to cisplatin treatment is acquired
resistance.58 While there are several diﬀerent explanations that
can account for this resistance, one important mechanism of
cisplatin resistance is decreased cellular accumulation
of the drug.59 Specifically, in an early study by Andrews and
coworkers, AAS was used to quantify cisplatin accumulation
into parent and cisplatin-resistant 2008 human ovarian carcinoma
cells. The resistant cells, which exhibited a 3.3-fold resistance,
displayed 50% less intracellular platinum than the parental cell
line.60 Since this study, there have been numerous investiga-
tions on various diﬀerent cell lines, many of which employed
AAS or ICP-MS, to corroborate this observation.
In a study done by the Sheldrick laboratory, a series of
rhodium(III) polypyridyl complexes (Fig. 10) was synthesized
and their cytotoxicities towards MCF-7 and HT-29 cancer cells
determined. It was noted that as the lipophilicity of the poly-
pyridyl ligand was increased, the cytotoxicity increased as well,
and they therefore measured the cellular accumulation of each
compound using AAS. As with the cisplatin example, the most
potent complexes exhibited the greatest amount of cellular
rhodium accumulation.61
The relationship between intracellular drug concentration
and eﬃcacy is not always as straightforward as in the above
studies, however. For example, in a study conducted by
Bugarcic and coworkers, three isomeric terphenyl Ru(II)
piano-stool complexes (Fig. 11) were examined. Their cytotoxi-
cities against two cisplatin sensitive and two cisplatin resistant
cancer cell lines were determined, and their intracellular
ruthenium concentrations were determined by AAS. Surpris-
ingly, the extent of ruthenium uptake of the three complexes
did not correlate at all with their diﬀerent cytotoxicities. In fact,
the most potent of the three complexes (the p-terp complex)
displayed the least amount of ruthenium uptake into the cells.
After numerous DNA binding studies, the authors attributed
Fig. 10 Chemical structures of Rh(III) polypyridyl complexes synthesized and
studied to monitor uptake. As complexes increased in lipophilicity (bpy to phen
to dpq to dppz to dppn derivatives), their cellular uptake into MCF-7 and HT-29
cells increased, resulting in increased potency.61
Fig. 11 Chemical structures of three isomeric terphenyl Ru(II) piano-stool com-
plexes studied by Bugarcic and coworkers.62 Uptake of the complexes into two
cisplatin resistant and two cisplatin sensitive cell lines was found not to correlate
with their potencies.
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the enhanced cytotoxicity of this complex to its ability to not only
covalently interact with DNA (as the other two isomers could) but
also intercalate into DNA.62 Perhaps the structural distortions
generated in this bound lesion produced a great cellular
response. In any case, this study nicely highlights the fact that
in many cases more information than just intracellular drug
concentration is necessary in order to explain biological activity.
One study that combines ICP-MS and fluorescence micro-
scopy to study the relationship among structure, activity, and
uptake was done by Louie and coworkers. In this work, a series
of luminescent rhenium(I) polypyridyl was examined (Fig. 12).
Here there was a direct correlation found between intracellular
rhenium concentrations, determined by ICP-MS, and cytotoxi-
cities in HeLa cells. Due to the luminescent nature of the
complexes, the authors were also able to monitor uptake in
live cells via confocal microscopy, and even observe the locali-
zation of the complexes in the mitochondria of the cells.63
Mechanisms of uptake
While knowing the relationship between the amount of a
therapeutic taken into a cell and the activity of the drug is
important, understanding how the compound gains entry into
the cell is likewise crucial for optimization of next-generation
complexes. The mechanism of cellular uptake of a drug can
direct its localization within the cell as well as the specificity of
a given compound for one cell type versus others.
The diﬀerent routes of entry into the cell include passive
diﬀusion, facilitated diﬀusion, active protein transport, and
endocytosis (Fig. 13). Passive diﬀusion is the movement of the
molecule of interest across the cell’s lipid bilayer, facilitated by
the concentration gradient. Facilitated diﬀusion is the trans-
port of the molecule of interest across the cell’s lipid bilayer,
facilitated by a membrane-bound transport protein such as a
channel or a passive carrier. Active transport is very similar, but
the proteins involved in this type of transport are membrane-
bound ATPases, meaning the process of moving a substance
from the outside of the cell to the inside uses ATP. Endocytosis
is a general term for the process by which the cell will ‘‘engulf’’
a molecule using a vesicle formed from the plasmamembrane.64
Endocytosis can be broken down into five diﬀerent categories:
macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated
endocytosis, clathrin- and caveolin-independent endocytosis,
and phagocytosis. All forms of endocytosis involve the
formation of a membrane compartment, and simply diﬀer in
the size and composition of the compartments involved.
Phagocytosis involves the uptake of particles larger than
0.5 mm in diameter, and thus is not applicable to small transition
metal complexes.65 Macropinocytosis involves ‘‘ruﬄing’’ of the
membrane to form large pockets greater than 1 mm in diameter,
or endocytic vesicles, which are filled with both extracellular
solvent and solute molecules. These vesicles are then broken
down by endosomes or lysosomes. Clathrin-mediated endo-
cytosis is mediated by ‘‘clathrin-coated pits’’, which are about
100 nm in diameter, and have a crystalline coat made up of
Fig. 12 Chemical structures (top) of a series of luminescent rhenium(I) poly-
pyridyl complexes by Louie and coworkers.63 Using ICP-MS, the authors were able
to correlate the cytotoxicities of these complexes in HeLa cells with intracellular
rhenium concentrations. Using fluorescence microscopy (bottom), the authors
were able to observe the localization of one such complex (structure shown in
bold, fluorescence shown on bottom left in red) in HeLa cells. The authors then
used MitoTracker (bottom middle in green) to show that the complex localizes
mainly in the mitochondria (bottom right, yellow shows the overlap). Copyright
(2012) American Chemical Society.
Fig. 13 Schematic diagram of the diﬀerent possible routes of entry into the cell taken by small complexes.
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transmembrane receptors associated with the protein clathrin.
These receptors bind their respective ligands (or a therapeutic
agent that resembles their ligand) and then pinch oﬀ to form
clathrin-coated vesicles (CCVs) which are internalized into the
cell. In caveolin-mediated endocytosis, flask-shaped pits in the
plasma membrane, about 60 to 80 nm in diameter, are shaped
by caveolin, a protein that binds cholesterol. Finally, in clathrin
and caveolin-independent endocytosis, small structures that
are 40 to 50 nm in diameter act as ‘‘rafts’’, freely diﬀusing along
the cell surface. These rafts will then be captured and inter-
nalized within any endocytic vesicle.66,67
However, just as membrane-bound proteins can facilitate
the entry of a complex into the cell, certain proteins, called
eﬄux transporters, can facilitate the extrusion of such com-
pounds from the cell. In fact, multidrug eﬄux pumps, which
can recognize multiple structurally dissimilar compounds, are
often responsible for chemotherapeutic resistance.68 The most
well-studied of such mammalian eﬄux transporters is the
ATP-binding cassette (ABC) family. These eﬄux transporters use
ATP hydrolysis to drive the extrusion of drugs from the cell, and
can do so against significant concentration gradients.69 The reason
behind the broad substrate specificity of these eﬄux transporters is
the presence of a large, flexible hydrophobic binding pocket which
allows for substrate binding via hydrophobic and electrostatic
interactions, rather than the specific hydrogen-bonding networks
present in less promiscuous transport proteins.70
A basic experiment in determining the mechanism of uptake
is determining whether the mechanism of uptake is energy-
dependent or -independent. Both passive and active diﬀusion
are energy-independent, while active transport and endocytosis
are energy-dependent. By incubating cells at low temperature
(4 1C) or in the presence of metabolic inhibitors (2-deoxyglucose
and olygomycin), processes that require energy will be blocked.
If the drug of interest has decreased uptake under these condi-
tions, the mechanism of uptake involves an energy-dependent
process, while if uptake is unchanged the mechanism is an
energy-independent process.71,72
Passive diﬀusion has the broadest range in substrates out of
all uptake mechanisms, and is therefore an attractive mode of
uptake for therapeutics. Uptake mediated by passive diﬀusion
is the most diﬃcult to modulate, but it can be done. Uptake of
positively charged molecules, such as many inorganic thera-
peutics, can be driven by the plasma membrane potential of the
cell. In mammalian cells, the membrane potential is generated
and maintained by a potassium concentration gradient. This
potential can be reduced either by using media with a
potassium concentration equal to the intracellular potassium
concentration, or by adding gramicidin A to the media, a
polypeptide that will form transmembrane channels which
allow unrestricted potassium traversal, thus destroying the
concentration gradient. In contrast, the cell can be hyper-
polarized by adding valinomycin to the media, a potassium-
specific ionophore that will increase potassium transportation
across the membrane.73
Protein-mediated transport, facilitated diﬀusion and active
transport have the capability of being cell-type or tissue-type
specific. This allows for the development of targeted drugs,
thus attenuating dose-limiting side eﬀects.74 This type of uptake
can be repressed by using known inhibitors of specific transport
proteins. If uptake of the compound of interest is decreased in
the presence of the inhibitor, then the respective transport
protein most likely is involved in uptake. Likewise, many eﬄux
transporters have known inhibitors; if uptake of a compound is
increased in the presence of an inhibitor, then the compound is
likely a substrate for the respective eﬄux protein.
As with protein-mediated transport, the diﬀerent types of
endocytosis can be mediated by using known inhibitors of the
diﬀerent processes. Ammonium chloride and chloroquine
diphosphate are general endocytosis inhibitors.75 Chlorpromazine
hydrochloride, monodansylcadaverine (MDC), and phenyl-
arsine oxide are inhibitors of clathrin-mediated endocytosis
and macropinocytosis.76 Filipin and nystatin selectively inhibit
caveolin-mediated endocytosis via cholesterol sequestration.77
Amiloride, as well as 5-(N,N-dimethyl) amiloride (DMA) and
5-(N-ethyl-N-isopropyl) amiloride (EIPA) inhibit macropinocyto-
sis and phagocytosis by obstructing Na+/H+ exchange.78
Cisplatin is the prototypical medicinal inorganic drug. There
have been many studies on the activity, uptake, and subcellular
distribution of this molecule and these serve as illustrations of
how mechanism may be elucidated. For many years it was
widely accepted that cisplatin entered the cell via passive
diﬀusion. In one such study on the mechanism of uptake of
cisplatin, Binks and Dobrota measured the amount of uptake of
cisplatin into rat small intestines using AAS. They found that
uptake of the drug was linear with respect to time and not
saturable up to a concentration of 1.0 mM. The authors also
found no change in uptake of cisplatin when the experiments
were repeated under metabolic inhibition, confirming that the
mechanism of uptake is energy-independent and through
passive diﬀusion.79 More recently, however, it was found that
several protein-mediated transport pathways can also be
responsible for cisplatin uptake. The most important of these
pathways are the organic cation transporters and the copper
influx transporter CTR1.80 To demonstrate the contribution of
CTR1 to cisplatin uptake, Howell and coworkers measures
cisplatin uptake in A2780 human ovarian cancer cells using
ICP-MS. They increased expression of CTR1 20-fold and found
that intracellular platinum levels increased by 55% after
24 hours of platinum incubation.81
Many ruthenium complexes are easy to monitor in uptake
studies owing to their strong luminescence. For example, we
have used flow cytometry to study the uptake of the lumines-
cent lipophilic ruthenium complex [Ru(DIP)2(dppz)]
2+ into
HeLa cells (Fig. 14). It was found that under metabolic inhibi-
tion, uptake of the ruthenium complex remained unchanged.
Additionally, increasing the incubation temperature from 4 1C
to 37 1C had no eﬀect on uptake. These experiments showed
that the mechanism of uptake was energy-independent. To rule
out facilitated diﬀusion by organic cation transporters (OCTs),
uptake of the ruthenium complex was also studied in the
absence and presence of a variety of OCT inhibitors (tetra-n-
alkylammonium salts, procainamide, and cimetidine), and was
found to be unaﬀected by the presence of these compounds.
Lastly, we examined the eﬀect of changes in the membrane
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potential on uptake of the ruthenium compound. When incu-
bated with a 170 mM potassium buﬀer (which reduces the
membrane potential to zero), uptake decreased substantially.
Furthermore, in the presence of valinomycin (which will
increase the membrane potential), uptake of the compound
increased substantially. Taken together, it was concluded that
uptake of [Ru(DIP)2(dppz)]
2+ was solely via passive diﬀusion.82
It is interesting to consider this complex being taken up at all
eﬃciently. The complex has a diameter of approximately 21 Å,
not unlike many small proteins, yet it is eﬃciently taken up
through the cell membrane to the cytoplasm and to some
extent to the nucleus of the cell.
In one last study by Pisani and coworkers, the mechanism of
cellular uptake of a dinuclear polypyridyl ruthenium(II) complex
(Fig. 15) into L1210 murine leukemia cells was determined
through flow cytometry experiments. In this study, the authors
found that varying the temperature of incubation from 4 1C to
20 1C to 37 1C had an eﬀect on uptake, with the 4 1C sample
having the least amount of intracellular ruthenium. Further-
more, when the cells were incubated with an increased amount
of glucose, uptake of the ruthenium complex was significantly
enhanced.
Conversely, under metabolic inhibition, uptake marginally
decreased. In order to rule out endocytosis, the authors
measured ruthenium uptake in the presence of a variety of
diﬀerent endocytosis inhibitors (chloroquine diphosphate, filipin,
dimethyl amiloride, ammonium chloride, and chlorpromazine
hydrochloride), and found that uptake was either unchanged or
increased in the presence of these inhibitors. Furthermore,
when incubated with a variety of OCT inhibitors (tetra-n-alky-
lammonium salts or procainamide), uptake remained
unchanged. The authors concluded that uptake was in large
part due to passive diﬀusion, with a minor contribution from
protein-mediated active transport.83 It is important to consider
that complexes so similar in chemical structure need have
similar mechanisms of uptake. Experiments need to be deter-
mined in each case to establish the uptake mechanism.
Subcellular localization of the metal complex
Once a therapeutic has entered the cell, there are a plethora of
diﬀerent organelles in which it can localize. Moreover, activities
and targets depend on where within the cell the complex
becomes localized. This localization can also determine
unwanted toxicities associated with a given complex.
Methods to monitor localization
The most commonly exploited technique for the subcellular
mapping of inorganic therapeutics is fluorescence microscopy.
However, this technique can only be used if the complex of
interest is inherently luminescent. Cells can be treated with the
luminescent drug of interest concomitantly with any of various
fluorescent organelle-specific probes. The extent of overlap
between the drug and the probe will provide information
on the localization of the drug. For example, Matson and
coworkers synthesized a variety of dppz complexes of Ru
derivatized with alkyl ether chains of various lengths and used
confocal laser scanning microscopy to study their subcellular
localization in CHO-K1 cells.84 Using various RNA andmembrane-
specific dyes, they found, perhaps not surprisingly, that the
least lipophilic compound localized in the nucleus, while the
most lipophilic localized in membranes.
While fluorescence microscopy has the capability of providing
a qualitative assessment of the localization of therapeutics in
living cells, due to diﬀerences in the quantum yields among
diﬀerent luminescent compounds, this technique cannot be
utilized to quantify the amount of drug localized inside the cell.
Furthermore, many metal-based luminescent compounds have
been shown to exhibit diﬀerent quantum yields depending on
the environment surrounding the compound,85 which further
complicates the quantitation of the localization of luminescent
metal complexes using this technique.
In a study by Groessl and co-workers, ICP-MS was used to
track the uptake and subcellular localization of cisplatin as
well as two ruthenium-based chemotherapeutics currently in
clinical trials, NAMI-A and KP1019. Reduced mitochondrial
accumulation of cisplatin was observed in cisplatin resistant
cells, while the ruthenium-based drugs were found to have
diﬀerent localization patterns than cisplatin, which did not
change from one cell type to the other.86
While AAS and ICP-MS can provide quantitative information
on the subcellular localization of inorganic complexes, the
process of sample preparation for these methods involves the
destruction of the cells, and therefore no structural information
is obtained. One method for the visualization of the subcellular
Fig. 14 [Ru(DIP)2(dppz)]
2+, a luminescent polypyridyl ruthenium complex that
enters HeLa cells via passive diﬀusion.82
Fig. 15 [Ru2(phen)4((bpy0)2(CH2)16)]
4+, a compound shown to enter L1210
murine leukemia cells via an energy-dependent mechanism as well as passive
diﬀusion.83
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localization of metal-based therapeutics while obtaining the
structural integrity of the cell is electron microscopy. Electron
microscopy has the advantage of providing spatial resolution
that is almost three orders of magnitude better than conven-
tional light microscopy, allowing for the resolution of structural
details in the nanometer range.87 Furthermore, the electron
dense property of metal ions can be detected inside cells by
electron microscopy due to mass contrast. In transmission
electron microscopy (TEM), cells are fixed, dehydrated with
organic solvent, embedded in resin, and then thinly sliced
(50 to 400 nm thick). These thin samples are then exposed to
an electron beam, which will be either scattered by regions of
high electron density (metal ions), or transmitted through low
electron density regions of the sample to a detector, which then
constructs a ‘‘contrast image’’ of the sample, where areas of
high electron density have higher contrast. In a study by
Van Rijt and coworkers, the distribution of a osmium(II) arene
complex in ovarian cancer cells was determined by TEM.
It was observed that upon treatment of A2780 cells with 5 mM
osmium complex, increased contrast was observed in
the mitochondria, nucleolus, and nuclear membrane. The
morphological changes associated with apoptosis were able to
be observed at the same time, illustrating the utility of electron
microscopy.88
Electron microscopy can in certain cases be combined with
elemental mapping to obtain a technique called energy-filtered
transmission electron microscopy (EFTEM). In this technique,
as the electrons from the electron beam hit the sample,
some will undergo an inelastic collision, losing an amount
of energy that is equivalent to the core atomic level of the
element that it just collided with. In this way, not only will
an image will be created with the resolution of electron micro-
scopy, but also element distribution maps can be obtained of
the sample.89
The last technique to consider here is nano-scale secondary
ion mass spectrometry (NanoSIMS). In this technique, a high-
energy primary ion beam bombards the surface of a sample,
‘‘sputtering’’ secondary ions which are then detected and
analyzed by a mass spectrometer.90 In this way, NanoSIMS
can provide spatial resolution up to 50 nm, as well as elemental
and isotopic information of the sample. This technique is in its
infancy and as such has not been widely utilized in the
subcellular mapping of metal based therapeutics. However, in
one study by the Berners-Price lab, a complementary EFTEM
and NanoSIMS study was performed on an antitumor gold(I)
phosphine complex.91 In this study, human breast cancer cells
(MDA) were treated with the gold complex and analyzed by both
EFTEM and NanoSIMS for subcellular gold localization. Using
EFTEM, the localization of gold could be observed, as well as
the morphological changes accompanying gold treatment.
NanoSIMS allowed for the mapping of 12C14N (to show cell
morphology), 31P (to show the location of nucleic acids),
197Au (to show localization of the therapeutic), and 34S
(to show the localization of thiols). The gold signal clearly co-
localized with the sulfur signal, thus supporting the idea that
the mechanism of action of Au(I) compounds involves the
inhibition of thiol-containing protein families.
Peptide conjugation
DNA is the cellular target of many inorganic chemotherapeutic
agents. As such, it is important for these complexes to localize
mainly in the nucleus of cells. One strategy to alter the
subcellular localization of a compound is through peptide
conjugation. Nuclear localization sequences (NLS) are small
peptides which, when appended to a protein, will in essence
allow the protein to be imported into the nucleus by nuclear
transport.92 As an example, Kirin and coworkers utilized the
NLS Pro-Lys-Lys-Lys-Arg-Lys-Val to enhance the uptake and
nuclear localization of the cobalt complex shown in Fig. 16
into HT-29 cells. AAS experiments revealed that not only does
the conjugate have enhanced uptake compared to the uncon-
jugated cobalt complex, but also the intracellular cobalt
concentration of the conjugate is higher than the extracellular
cobalt concentration. Furthermore, the fraction of intracellular
cobalt localized in the nucleus increased for the conjugates
compared to the unconjugated cobalt complex.93
However, in the design of peptide-therapeutic conjugates,
care must be taken to ensure that the conjugate itself still has
the same biological target as the unconjugated molecule. For
example, in an attempt to increase and accelerate cellular
uptake of our rhodiummetalloinsertors, the [Rh(phen)(bpy0-Arg8)-
(chrysi)]11+ complex shown in Fig. 17 was synthesized. Uptake
studies conducted on the fluorescein-appended analogue
Fig. 16 The peptide conjugate studied by Kirin and coworkers. Upon conjuga-
tion of the cobalt complex to the nuclear localization peptide, uptake of the
complex into the nucleus of HT-29 cells increased significantly.93
Fig. 17 The rhodium metalloinsertor–peptide conjugate synthesized in order to
accelerate uptake. While uptake is accelerated upon conjugation of the metal-
loinsertor to the octaarginine peptide, the presence of the octaarginine increases
the nonspecific binding aﬃnity of the complex for matched and mismatched DNA.
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confirmed fast (within 60 min) nuclear uptake into HeLa cells.
However, DNA binding studies revealed that, with the octaargi-
nine appendage, the nonspecific binding aﬃnity of both
complexes for mismatched and matched DNA increased, due
to the substantial added positive charge of the peptide.94 In
fact, studies of cellular proliferation with the metalloinsertor–
peptide conjugate confirmed that the complexes no longer
showed the preferential inhibition of MMR-deficient cells, as
expected if specific binding only to mismatched DNA was lost.
One route to restore specificity would be to include a self-
cleavable linker so that the conjugate would be removed once
inside the nucleus. The work thus illustrates the utility but also
subtle new issues that arise with peptide conjugates for ther-
apeutic applications.
Many laboratories append fluorescent tags onto molecules
of interest to follow their subcellular localization. The process
of appending a fluorescent tag to the molecule of interest can,
however, also alter the subcellular localization.95 As an illustra-
tion, we examined the localization properties of two Ru(dppz)–
peptide conjugates, one with and one without a fluorescent tag
(Fig. 18). The conjugate with only the octaarginine peptide was
localized throughout the cytoplasm in punctate distributions
and was completely absent from the nucleus. On the other
hand, the conjugate with both octaarginine and fluorescein
exhibited nuclear staining when incubated under the same
conditions as the previous conjugate. This study clearly shows
the consequences of appending fluorescent tags to non-fluores-
cent molecules in order to study their subcellular localizations.
Combination of techniques
In order to gain a complete understanding of the mechanism of
action of a given complex, the techniques discussed here must
be combined. For example, in a recent study in our laboratory,
the activity, uptake, and subcellular localization of ten diﬀerent
rhodium metalloinsertors were examined (Fig. 19). While the
binding aﬃnities of all ten compounds were found to be within
an order of magnitude of each other, the abilities of the
compounds to selectively target MMR-deficient cells over
MMR-proficient cells varied dramatically. The more lipophilic
compounds showed the least selectivity for the MMR-deficient
cells. ICP-MS was then used to determine the intracellular
rhodium concentrations of all ten compounds over a 24 hour
time course in human colorectal HCT116 cells. The diﬀerent
compounds had drastically diﬀerent patterns of rhodium
uptake over time, reflecting diﬀerent mechanisms of uptake.
Fig. 18 Chemical structures (top) and confocal microscopy images (bottom) of
the two metal–peptide fluorophore conjugates examined in our laboratory. The
octaarginine conjugate (left) displays only cytosolic localization, while the
octaarginine fluorescein conjugate (right) exhibit nuclear localization.
Fig. 19 Chemical structures of ten rhodium metalloinsertors studied in our laboratory.While all compounds were localized in the nucleus of HCT116 cells at suﬃcient
concentrations for mismatch binding, only the compounds with low mitochondrial rhodium accumulation exhibited preferential targeting of MMR-deficient cells over
MMR-proficient cells.96
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However, the amount of intracellular rhodium did not correlate
at all with their biological activities. ICP-MS was then combined
with organelle fractionation techniques in order to provide us
with quantitative information about the subcellular localiza-
tion of the rhodium metalloinsertors. After treating HCT116
cells with the various compounds, the nuclei and mitochondria
were isolated and tested for rhodium content using ICP-MS. It
was found that while all compounds tested were localized in
the nucleus at concentrations suﬃcient for DNA mismatch
binding, those with higher mitochondrial rhodium accumula-
tion showed lower specificity for MMR-deficient cells over
MMR-proficient cells. Binding to DNA in the mitochondria
was deleterious to the unique biological activity. Thus this
study established clearly that it is mismatches in genomic
DNA that are the ultimate target of rhodium metalloinsertors
and that are responsible for their unique biological activity.96
Conclusion
The development of new cell-selective therapeutic agents is
imperative, and metal complexes oﬀer a wealth of possibilities
for new design. Structural characterization of the interaction
between a given complex and its target is critical, providing
insight as to what changes can be made to increase aﬃnity and
specificity for the target. Likewise, structure–function relation-
ships can provide critical information. Also important is devel-
oping an understanding of the relationship between uptake
and activity. The knowledge of where within the cell the
complex is being shuttled is a powerful tool, and a possible
driver in the design of new therapeutics with improved eﬀec-
tiveness. In general, metal complexes oﬀer the tools, flexibility
in ligand substitution and varied techniques to monitor their
path and biological fate within the cell.
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